Skip to main content
OpenTrials
Completed

NCT Number: NCT04914429

A Study of Guselkumab (TREMFYA) in Chinese Participants With Moderate to Severe Plaque Psoriasis

The purpose of this study is to evaluate the efficacy, safety and tolerability of guselkumab in the treatment of Chinese participants with moderate to severe plaque psoriasis.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Psoriasis Skin Diseases Skin Diseases, Papulosquamous Skin and Connective Tissue Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Beijing Tongren Hospital, CMU, Beijing, China

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Have a diagnosis of plaque psoriasis with or without psoriatic arthritis for at least 6 months before screening
  • A woman of childbearing potential must have a negative urine pregnancy test at screening and at baseline
  • Agree not to receive a live virus or live bacterial vaccination during the study, or within 3 months after the last administration of study drug
  • Agree to avoid prolonged sun exposure and avoid use of tanning booths or other ultraviolet (UV) light sources during study
  • Must sign an informed consent form (ICF) indicating that he or she understands the purpose of, and procedures required for, the study and is willing to participate in the study

Exclusion criteria

  • Has a nonplaque form of psoriasis (example, erythrodermic, guttate, or pustular)
  • Has a history of or current signs or symptoms of liver or renal insufficiency (estimated creatinine clearance below 60 milliliter/minute [mL/min]); significant, progressive, or uncontrolled cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, psychiatric, or metabolic disturbances
  • Currently has a or has a history of malignancy within 5 year before screening (exceptions are nonmelanoma skin cancer that has been adequately treated with no evidence of recurrence for at least 3 months before the first study drug administration and cervical carcinoma in situ that has been treated with no evidence of recurrence for at least 3 months before screening, or malignancy, which is considered cured with minimal risk of recurrence)
  • History of, or ongoing, chronic or recurrent infectious disease, including but not limited to, recurrent sinopulmonary infections, bronchiectasis, recurrent renal/urinary tract infection (example, recurrent pyelonephritis, recurrent cystitis), fungal infection (mucocutaneous candidiasis), an open, draining, or infected skin wound, or an ulcer
  • Has previously received guselkumab

Treatment and study plan

Guselkumab

Drug

Guselkumab 100 mg will be administered as a SC injection.

Other names: TREMFYA

Placebo

Drug

Matching placebo will be administered as a SC injection.

Primary outcomes

  1. Percentage of Participants who Achieve a Psoriasis Area and Severity Index (PASI) 90 Response at Week 16

    Time frame: Week 16

    The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed separately for erythema, induration and scaling, which are each rated on a scale of 0 to 4 that is none to maximum severity. The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease. A PASI 90 response is defined as greater than or equal to (>=)90 percent (%) improvement in PASI score.

  2. Percentage of Participants who Achieve an Investigator's Global Assessment (IGA) Score of Cleared (0) or Minimal (1) at Week 16

    Time frame: Week 16

    The IGA documents the investigator's assessment of the participant's psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4).

  3. Number of Participants with Adverse Events (AEs)

    Time frame: Up to Week 56

    An AE is any untoward medical occurrence in a participant participating in a clinical study that does not have a causal relationship with the pharmaceutical/biological agent under study.

  4. Number of Participants with Serious Adverse Events (SAEs)

    Time frame: Up to Week 56

    SAE is any untoward medical occurrence that at any dose may results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is a suspected transmission of any infectious agent via a medicinal product.

  5. Number of Participants with Reasonably Related Adverse Events (AEs)

    Time frame: Up to Week 56

    An AE is any untoward medical occurrence in a participant participating in a clinical study that does not have a causal relationship with the pharmaceutical/biological agent under study.

  6. Number of Participants with AEs Leading to Discontinuation of Study Intervention

    Time frame: Up to Week 56

    Number of participants with AEs leading to discontinuation of study intervention will be reported.

  7. Number of Participants with Infections

    Time frame: Up to Week 56

    Number of participants with infections including serious infections, and infections requiring oral or parenteral antimicrobial treatment will be reported.

  8. Number of Participants with Serious Hypersensitivity Reactions

    Time frame: Up to Week 56

    Number of participants with serious hypersensitivity reactions (such as anaphylaxis, urticaria, pruritis, angioedema, wheezing, dyspnea, or hypotension) will be reported.

  9. Number of Participants with Injection-site Reactions

    Time frame: Up to Week 56

    An injection-site reaction is any unfavorable or unintended sign that occurs at the study drug injection site. Injection sites will be evaluated for reactions and any injection-site reaction will be recorded as an AE.

  10. Number of Participants with Change from Baseline in Laboratory Abnormalities

    Time frame: Up to Week 56

    Number of participants with change from baseline in laboratory abnormalities (chemistry, hematology) will be reported.

  11. Number of Participants with Laboratory Abnormalities with Maximum Toxicity Grades

    Time frame: Up to Week 56

    Number of participants with laboratory abnormalities (hematology, chemistry) with maximum toxicity grades will be reported. A higher grade indicates more severity.

  12. Number of Participants with Change from Baseline in Vital Signs

    Time frame: Up to Week 56

    Number of participants with change from baseline in vital signs (temperature, heart rate, respiratory rate, blood pressure) will be reported.

Secondary outcomes

  1. Percentage of Participants who Achieve a PASI 100, PASI 75, and PASI 50 Response Over Time

    Time frame: Week 0, 4, 12, 16, 20, 28, 36, 44, 48

    The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed separately for erythema, induration and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease. A PASI 100, 75, and 50 response is defined as 100%, >=75%, and >=50% improvement in PASI score respectively.

  2. Percentage of Participants who Achieve a PASI 90 Response Over Time

    Time frame: Week 0, 4, 12, 16, 20, 28, 36, 44, 48

    The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed separately for erythema, induration and scaling, which are each rated on a scale of 0 to 4 that is none to maximum severity. The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease. A PASI 90 response is defined as >=90% improvement in PASI score.

  3. Percentage of Participants who Achieve an IGA Score of Cleared (0) or Minimal (1) Over Time

    Time frame: Week 0, 4, 12, 16, 20, 28, 36, 44, 48

    Percentage of participants who achieve an IGA score of cleared (0) or minimal (1) over time will be reported.

  4. Change from Baseline in Dermatology Life Quality Index (DLQI) Score Over Time

    Time frame: Baseline, Week 4, 16, 28, 48

    The DLQI is a dermatology-specific quality of life (QoL) instrument designed to assess the impact of the disease on a participant's QoL. It is a 10 item patient-reported outcome(s) (PRO) questionnaire that, in addition to evaluating overall QoL, can be used to assess 6 different aspects that may affect QoL: symptoms and feelings, daily activities, leisure, work or school performance, personal relationships, and treatment. The DLQI produces a numeric score that can range from 0 to 30. A higher score indicates more severe disease.

  5. Percentage of Participants who Maintain PASI 90 Response at Week 48 Among Participants who were PASI 90 Responders at Week 16 in Guselkumab Group

    Time frame: Week 48

    The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed separately for erythema, induration and scaling, which are each rated on a scale of 0 to 4 that is none to maximum severity. The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease. A PASI 90 response is defined as >=90% improvement in PASI score.

  6. Percentage of Participants who Maintain IGA Score of Cleared (0) or Minimal (1) at Week 48 Among Participants who Achieved IGA 0/1 at Week 16 in Guselkumab Group

    Time frame: Week 48

    Percentage of participants who maintain IGA score of cleared (0) or minimal (1) at Week 48 among participants who achieved IGA 0/1 at Week 16 in guselkumab group will be reported.

  7. Percentage of Participants who Achieve an IGA Score of Cleared (0) and an IGA Score of Mild or Better (Less Than or Equal to [<=] 2) Over Time

    Time frame: Week 0, 4, 12, 16, 20, 28, 36, 44, 48

    Percentage of participants who achieve an IGA score of cleared (0) and an IGA score of mild or better (<=2) over time will be reported.

  8. Percentage of Participants who Achieve a DLQI Score of 0 or 1 Over Time Among Participants with Baseline DLQI Greater Than (>) 1

    Time frame: Week 0, 4, 16, 28, 48

    Percentage of participants who achieve a DLQI score of 0 or 1 over time among participants with baseline DLQI >1 will be reported.

  9. Percentage of Participants With a Reduction of 5 or More Points in DLQI Score Over Time

    Time frame: Week 0, 4, 16, 28, 48

    Percentage of participants with a reduction of 5 or more points in DLQI score over time will be reported.

  10. Percent Change from Baseline in Nail Psoriasis Severity Index (NAPSI) Over Time Among Participants with Nail Psoriasis at Baseline

    Time frame: Baseline, Week 16, 28, 36, 48

    The NAPSI is an index used for assessing and grading the severity of nail psoriasis. A target nail representing the worst nail psoriasis is divided into quadrants and is graded for nail matrix psoriasis (pitting, leukonychia, red spots in the lunula, and nail plate crumbling) and nail bed psoriasis (onycholysis, splinter hemorrhages, oil drop discoloration, and nail bed hyperkeratosis), each on a scale of 0-4 (A higher score indicates more severity). The sum of these scores is the total NAPSI score (0=no psoriasis to 8=psoriasis present in all 4 quadrants of the target nail).

  11. Percentage of Participants with an Scalp-Specific Investigator Global Assessment (ss-IGA) Score of Absence of Disease (0) or Very Mild Disease (1) Over Time Among Participants with Scalp Psoriasis and an ss-IGA Score >=2 at Baseline

    Time frame: Week 0, 16, 28, 36, 48

    The ss-IGA instrument is used to evaluate the disease severity of scalp psoriasis. The lesions are assessed in terms of the clinical signs of redness, thickness, and scaliness which are scored as: absence of disease (0), very mild disease (1), mild disease (2), moderate disease (3), and severe disease (4).

  12. Serum Concentration of Guselkumab Over Time

    Time frame: Week 0, 4, 16, 20, 36, 44, 56

    Serum concentrations of guselkumab over time will be reported.

  13. Number of Participants with Antibodies to Guselkumab

    Time frame: Week 0, 16, 44, 56

    Number of participants with antibodies to guselkumab through week 56 will be reported.

  14. Maximum Titer of Antibodies to Guselkumab Through Week 56

    Time frame: Week 0, 16, 44, 56

    Maximum titer of antibodies to guselkumab through Week 56 will be reported.

Sponsors and collaborators

Lead sponsor

Janssen Research & Development, LLC

Industry

Registry information

Official study title

A Phase 4, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Guselkumab (TREMFYA) in Chinese Participants With Moderate to Severe Plaque Psoriasis

Important dates

Study start
2021
Primary completion
2023
Study completion
2023
First posted
Jun 4, 2021
Registry last updated
Oct 12, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.